Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.17 CAD
Change Today 0.00 / 0.00%
Volume 213.5K
SBM On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 3:59 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

sirona biochem corp (SBM) Snapshot

Open
C$0.17
Previous Close
C$0.17
Day High
C$0.17
Day Low
C$0.16
52 Week High
08/6/14 - C$0.20
52 Week Low
07/18/14 - C$0.09
Market Cap
22.1M
Average Volume 10 Days
869.5K
EPS TTM
C$-0.03
Shares Outstanding
130.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SIRONA BIOCHEM CORP (SBM)

Related News

No related news articles were found.

sirona biochem corp (SBM) Related Businessweek News

No Related Businessweek News Found

sirona biochem corp (SBM) Details

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada. The company develops programs in three areas, including diabetes and cancer therapeutics; anti-aging and depigmenting agent in cosmeceuticals; biological ingredients, such as inducers and adjuvants for biological development. It develops a sodium glucose co-transporter inhibitor for the treatment of Type 2 diabetes; and a cancer vaccine antigen. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Founded in 2006

sirona biochem corp (SBM) Top Compensated Officers

Founder, Chairman of the Board, Interim Chief...
Total Annual Compensation: C$95.0K
Chief Financial Officer and Director
Total Annual Compensation: C$102.0K
Compensation as of Fiscal Year 2013.

sirona biochem corp (SBM) Key Developments

Sirona Biochem Corp. Announces Positive Results with SBM-TFC-837 for Anti-Aging and Regenerative Medicine

Sirona Biochem Corp. announced that its French partner, Biogalenys, observed positive effects of Sirona's glycoprotein SBM-TFC-837 on human fibroblasts in preliminary, in vitro, studies in response to the stressed condition of ultraviolet (UV) radiation. The results of these studies demonstrated a dramatic increase in percent cell viability over time with SBM- TFC-837, which suggests glycoprotein plays an important role in protection against UV induced cell death. Further studies are ongoing and will continue to assess cell stressors and viability. The compounds may have applications in: Anti-aging cosmetic product since 80% of visible aging is directly related to cell death Cryopreservation; regenerative and protective cosmetic or pharmaceutical product for healing, wound care, hypothermic protection, sunscreen, post burn /radiotherapy; regenerative and protective pharmaceutical product against stress response in renal reperfusion and the improvement of engraftment; pharmaceutical product used in organ transplantation solution (for example Wisconsin solution); regenerative and preservative product for preservation of stem cells, -islet cells, red blood cells, adipocytes and platelets as well as tissues including reconstituted human epithelial cells, skin explants and cornea; and preservative for vaccines.

Sirona Biochem Corp. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 04:00 PM

Sirona Biochem Corp. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 04:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan. Speakers: Attila Hajdu, Chief Business Development Officer.

Sirona Biochem Corp. Announces Successful Development of A Third Skin Lightener with Superior Safety and Efficacy

Sirona Biochem Corp. announced the successful development of a third innovative skin-lightening compound that has superior safety, with zero hydroquinone release and 8 times the efficacy of deoxyarbutin. This innovation was made possible through Sirona's platform technology of fluorination chemistry and through support of the European Union and the European Regional Development Fund (E.R.D.F.). Sirona Biochem has conducted comprehensive safety and efficacy studies in accordance with the standards of the cosmetic industry, demonstrating that SBM-TFC-1067 has the following scientifically proven properties: A superior safety profile over deoxyarbutin, with zero hydroquinone released in all chemical and biological tested conditions; 8 times the efficacy of deoxyarbutin; A high capacity to reach the site of action in the epidermis; Additional antioxidant properties.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBM:CN C$0.17 CAD 0.00

SBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBM.
View Industry Companies
 

Industry Analysis

SBM

Industry Average

Valuation SBM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 88.3x
Price/Book 10.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 92.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIRONA BIOCHEM CORP, please visit www.sironabiochem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.